38404868|t|Lipidomics based on UHPLC/Q-TOF-MS to characterize lipid metabolic profiling in patients with newly diagnosed type 2 diabetes mellitus with dyslipidemia.
38404868|a|Dyslipidemia often accompanies type 2 diabetes mellitus (T2DM). Elevated blood glucose in patients commonly leads to high levels of lipids. Lipid molecules can play a crucial role in early detection, treatment, and prognosis of T2DM with dyslipidemia. Previous lipid studies on T2DM mainly focused on Western diabetic populations with elevated blood glucose. In this research, we investigate both high blood sugar and high lipid levels to better understand changes in plasma lipid metabolism in newly diagnosed Chinese T2DM patients with dyslipidemia (NDDD). We used a plasma lipid analysis method based on ultra-high performance liquid chromatography coupled with mass spectrometry technology (UHPLC-MS) and statistical analysis to characterize lipid profiles and identify potential biomarkers in NDDD patients compared to healthy control (HC) subjects. Additionally, we examined the differences in lipid profiles between hyperlipidemia (HL) patients and HC subjects. We found significant changes in 15 and 23 lipid molecules, including lysophosphatidylcholine (LysoPC), phosphatidylcholine (PC), phosphatidylethanolamine (PE), sphingomyelin (SM), and ceramide (Cer), in the NDDD and HL groups compared to the HC group. These altered lipid molecules are associated with five metabolic pathways, with sphingolipid metabolism and glycerophospholipid metabolism being the most relevant to glucose and lipid metabolism changes. These lipid biomarkers are strongly correlated with traditional markers of glucose and lipid metabolism. Notably, Cer(d18:1/24:0), SM(d18:1/24:0), SM(d18:1/16:1), SM(d18:1/24:1), and SM(d18:2/24:1) were identified as essential potential biomarkers closely linked to clinical parameters through synthetic analysis of receiver operating characteristic curves, random forest analysis, and Pearson matrix correlation. These lipid biomarkers can enhance the risk prediction for the development of T2DM in individuals with dyslipidemia but no clinical signs of high blood sugar. Furthermore, they offer insights into the pathological mechanisms of T2DM with dyslipidemia.
38404868	51	56	lipid	Chemical	MESH:D008055
38404868	80	88	patients	Species	9606
38404868	110	134	type 2 diabetes mellitus	Disease	MESH:D003924
38404868	140	152	dyslipidemia	Disease	MESH:D050171
38404868	154	166	Dyslipidemia	Disease	MESH:D050171
38404868	185	209	type 2 diabetes mellitus	Disease	MESH:D003924
38404868	211	215	T2DM	Disease	MESH:D003924
38404868	227	240	blood glucose	Chemical	MESH:D001786
38404868	244	252	patients	Species	9606
38404868	286	292	lipids	Chemical	MESH:D008055
38404868	294	299	Lipid	Chemical	MESH:D008055
38404868	382	386	T2DM	Disease	MESH:D003924
38404868	392	404	dyslipidemia	Disease	MESH:D050171
38404868	415	420	lipid	Chemical	MESH:D008055
38404868	432	436	T2DM	Disease	MESH:D003924
38404868	463	471	diabetic	Disease	MESH:D003920
38404868	498	511	blood glucose	Chemical	MESH:D001786
38404868	556	567	blood sugar	Chemical	MESH:D001786
38404868	577	582	lipid	Chemical	MESH:D008055
38404868	629	634	lipid	Chemical	MESH:D008055
38404868	673	677	T2DM	Disease	MESH:D003924
38404868	678	686	patients	Species	9606
38404868	692	704	dyslipidemia	Disease	MESH:D050171
38404868	706	710	NDDD	Disease	
38404868	730	735	lipid	Chemical	MESH:D008055
38404868	900	905	lipid	Chemical	MESH:D008055
38404868	952	956	NDDD	Disease	
38404868	957	965	patients	Species	9606
38404868	1054	1059	lipid	Chemical	MESH:D008055
38404868	1077	1091	hyperlipidemia	Disease	MESH:D006949
38404868	1093	1095	HL	Disease	MESH:D006949
38404868	1097	1105	patients	Species	9606
38404868	1165	1170	lipid	Chemical	MESH:D008055
38404868	1192	1215	lysophosphatidylcholine	Chemical	MESH:D008244
38404868	1217	1223	LysoPC	Chemical	MESH:D008244
38404868	1226	1245	phosphatidylcholine	Chemical	MESH:D010713
38404868	1247	1249	PC	Chemical	MESH:D010713
38404868	1252	1276	phosphatidylethanolamine	Chemical	MESH:C483858
38404868	1278	1280	PE	Chemical	MESH:C483858
38404868	1283	1296	sphingomyelin	Chemical	MESH:D013109
38404868	1298	1300	SM	Chemical	MESH:D013109
38404868	1307	1315	ceramide	Chemical	MESH:D002518
38404868	1317	1320	Cer	Chemical	MESH:D002518
38404868	1330	1334	NDDD	Disease	
38404868	1339	1341	HL	Disease	MESH:D006949
38404868	1389	1394	lipid	Chemical	MESH:D008055
38404868	1455	1467	sphingolipid	Chemical	MESH:D013107
38404868	1483	1502	glycerophospholipid	Chemical	MESH:D020404
38404868	1541	1548	glucose	Chemical	MESH:D005947
38404868	1553	1558	lipid	Chemical	MESH:D008055
38404868	1585	1590	lipid	Chemical	MESH:D008055
38404868	1654	1661	glucose	Chemical	MESH:D005947
38404868	1666	1671	lipid	Chemical	MESH:D008055
38404868	1693	1696	Cer	Chemical	MESH:D002518
38404868	1710	1712	SM	Chemical	MESH:D013109
38404868	1726	1728	SM	Chemical	MESH:D013109
38404868	1742	1744	SM	Chemical	MESH:D013109
38404868	1762	1764	SM	Chemical	MESH:D013109
38404868	1999	2004	lipid	Chemical	MESH:D008055
38404868	2071	2075	T2DM	Disease	MESH:D003924
38404868	2096	2108	dyslipidemia	Disease	MESH:D050171
38404868	2139	2150	blood sugar	Chemical	MESH:D001786
38404868	2221	2225	T2DM	Disease	MESH:D003924
38404868	2231	2243	dyslipidemia	Disease	MESH:D050171
38404868	Association	MESH:D008055	MESH:D050171
38404868	Association	MESH:D005947	MESH:D008055
38404868	Association	MESH:D008244	MESH:D006949
38404868	Association	MESH:D005947	MESH:D013107
38404868	Association	MESH:D005947	MESH:D020404
38404868	Association	MESH:D002518	MESH:D006949
38404868	Association	MESH:D008055	MESH:D003924
38404868	Association	MESH:D008055	MESH:D010713
38404868	Association	MESH:D010713	MESH:D006949
38404868	Positive_Correlation	MESH:D013109	MESH:D006949
38404868	Association	MESH:D008055	MESH:D006949
38404868	Association	MESH:D002518	MESH:D008055
38404868	Association	MESH:D008055	MESH:D013109
38404868	Association	MESH:D001786	MESH:D008055
38404868	Association	MESH:D008055	MESH:D013107
38404868	Association	MESH:D008055	MESH:D020404
38404868	Association	MESH:C483858	MESH:D006949

